Alerta

METHODS FOR DETERMINING PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) AND ITS USE FOR DIAGNOSTIC PURPOSE

Resumen de: US20260251655A1

0000 The present invention is directed to methods for determining the level of PAM and/or its isoforms and/or fragments thereof in a bodily fluid or a tissue sample using an assay, wherein said assay is comprising at least one binder that is directed to a conformational epitope of PAM, and its use for diagnostic purpose.

METHOD OF ANALYZING NEURONS, DEVICE FOR ANALYZING NEURONS, AND COMPUTER PROGRAM

Resumen de: US20260251634A1

A method of analyzing neurons includes: identifying a cell region by identifying a region of a neurite or a region of a cell body of a neuron on the basis of time-series images obtained by imaging the neuron in time series; detecting aggregates by imaging, in time series, first fluorescent protein tagged to specific protein expressed in the neuron and detecting presence or absence of aggregates of the specific protein aggregated in the region of the neurite or the region of the cell body identified in the identifying the cell region on the basis of luminance of the first fluorescent protein included in the time-series images; and performing an analysis by classifying the neuron into a plurality of groups on the basis of a detection result of the detecting the aggregates and analyzing a survival state of the neuron for each of the groups.

METHODS AND COMPOSITIONS FOR USING EXTRACELLULAR PARTICLES TO DETECT PATHOLOGY-RELATED PATHWAYS

Resumen de: WO2025085755A1

Disclosed are methods of detecting or quantifying a pathology -related or pathology-protective-pathway in a subject comprising combining a first ligand with a sample obtained from the subject comprising an extracellular particle, wherein the first ligand binds to a cell-type specific marker on the extracellular particle; combining a second ligand with the sample, wherein the second ligand binds to a pathology-related or pathology-protective pathway molecule on the extracellular particle; combining a donor bead to the sample, wherein the donor bead binds to the first ligand or second ligand; combining an acceptor bead to the sample, wherein the acceptor bead binds to the first ligand or second ligand, wherein the donor bead and acceptor bead do not bind to the same ligand; triggering the donor bead to activate the acceptor bead to produce a signal; wherein the amount, presence, or absence of a signal indicates the amount, presence, or absence of a pathological condition in the subject.

EXTRACELLULAR VESICLE COMPOSITIONS AND USES THEREOF

Resumen de: WO2025081242A1

The present disclosure relates to compositions comprising a solid surface and two or more capture agents that bind to extracellular vesicles (EVs) for capturing EVs derived from cells of the nervous system. The present disclosure further relates to methods or uses of such compositions for treating, diagnosing and/or assessing the likelihood of a subject suffering from a neurodegenerative disease.

BACE-1 IN BRAIN-DERIVED EXTRACELLULAR VESICLES AS A BIOMARKER FOR ALZHEIMER'S DISEASE

Resumen de: EP4796928A1

The present disclosure relates to an in vitro method for diagnosing Alzheimer's disease (AD) in a subject, the method comprising a step of determining the level of β-secretase 1 protein (BACE-1) comprised in a population of brain-derived extracellular vesicles (BDEVs) in an isolated sample obtained from the subject, particularly wherein the population of BDEVs carry neuroligin-3 (NLGN3), wherein when the level of BACE-1 is equal to or higher than a reference this is indicative of a positive diagnosis of Alzheimer's disease. Also provided herein are methods of determining the classification of a subject according to the A/T/N system, methods for recommending a medical regimen, methods for determining therapeutic efficacy of a medical regiment, as well as methods of treatment for AD and AD-associated pathologies in a subject. Finally, the present disclosure provides kits and devices comprising: a) means for capturing a population of brain-derived extracellular vesicles; b) means for detecting the presence and/or for determining the level of BACE-1 protein; and optionally, c) a solid support.

ALPHA-SYNUCLEIN DETECTION USING BEADS

Resumen de: EP4796929A2

0001 A method is provided for determining the presence of soluble, misfolded α-synuclein protein in a biological sample. The method comprises contacting the biological sample with a pre-incubation mixture, the pre-incubation mixture comprising: a monomeric α-synuclein protein; a buffer composition; a salt; and an indicator, to form an incubation mixture. An incubation cycle is conducted on the incubation mixture in the presence of either a silicon nitride bead or a borosilicate glass bead having a diameter of from about 1 mm to about 5 mm. The method further comprises determining if a detectable amount of misfolded α-synuclein aggregate is present in the biological sample.

METHODS FOR IN SITU TRANSCRIPTOMICS AND PROTEOMICS

Resumen de: EP4796930A2

Disclosed herein are methods of detecting a plurality of targets comprising different nucleic acid sequences or different proteins within an optically resolved volume of a cell in situ.

プラズマローゲンの低減されたレベルに関連する出生後状態の動物モデル

Resumen de: WO2025035206A1

The invention describes a transgenic, non-human animal model, for testing post-natal, conditionally inducible plasmalogen deficiency. The animal model's genome is equipped with a gene that is capable of regulating the plasmalogen biosynthetic pathway, where the gene has a regulatory region. Within the regulatory region there is at least one conditionally inducible gene editing site that blocks the expression of the gene when edited. The genome also has a nucleic acid editing sequence integrated at a separate locus from the gene which encodes a gene product. The gene product edits the gene editing site when conditionally induced that eventually down-regulates or disrupts the plasmalogen biosynthetic pathway. Methods and uses involving the transgenic, non-human animal model are also provided.

神経疾患、特に運動ニューロン疾患のためのペプチドバイオマーカー

Resumen de: WO2025032091A1

The present invention relates to a splice variant of a CERT1 protein that acts as a biomarker for a TDP-43 pathology, in particular motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), but also other neurological diseases, such as Alzheimer's disease. In particular, the present invention relates to methods for identifying a splice variant of CERT1 comprising a cryptic peptide sequence, and to related methods of identifying a TDP-43 pathology and/or reduced TDP-43 function in a subject and to methods for predicting whether a therapy is likely to be successful. Also claimed are antibodies binding to the CERT1 splice variant and kits comprising the antibody.

用于HIV相关无症状神经认知障碍诊断的代谢组学-肠道微生物标志物组合及其应用

Resumen de: CN122629217A

0001 本发明公开了一种用于HIV相关无症状神经认知障碍（ANI）诊断的代谢组学‑肠道微生物标志物组合，包括代谢组学标志物和肠道微生物标志物，其中代谢组学标志物包括血浆标志物和粪便标志物，血浆标志物包括Asp‑Asn和花生四烯酸，粪便标志物包括组氨酸、赖氨酸、鸟氨酸以及吲哚乳酸；肠道微生物标志物包括门水平标志物和属水平标志物，门水平标志物包括厚壁菌门、放线菌门以及变形菌门微生物，属水平标志物包括普拉梭菌属、小杆菌属、克雷伯氏菌属以及普雷沃氏菌属。该标志物组合整合了代谢组学与肠道微生物的核心差异特征，诊断特异性和敏感性高，能够有效区分ANI患者与CI患者及健康人群，为HAND靶向干预提供了明确靶点，具有重要的临床应用价值。

用于磷酸化Tau蛋白pTau217检测的抗体、免疫检测方法及应用

Resumen de: CN122628189A

0001 本申请公开了一种用于磷酸化Tau蛋白pTau217检测的抗体、免疫检测方法及应用。本申请抗体包括T217‑3D6抗体；T217‑3D6的轻链CDR1、CDR2和CDR3依序为SEQ ID NO.1至3所示序列，重链CDR1、CDR2和CDR3依序为SEQ ID NO.4至6所示序列。基于本申请抗体对磷酸化Tau蛋白pTau217进行免疫检测，操作简单、灵敏度高、特异性强，可实现磷酸化Tau蛋白pTau217快速检测，对评估Tau蛋白磷酸化水平和Tau蛋白pTau217磷酸化相关检测具有重要意义。

表位分子印迹膜库的构建结合场效应晶体管用于检测超灵敏生物检测的方法

Resumen de: CN122631731A

0001 本发明公开了表位分子印迹膜库的构建结合场效应晶体管用于检测超灵敏生物检测的方法，用于多种生物分子的检测；同时将制备的表位分子印迹膜库与场效应晶体管技术相结合开发一种高灵敏生物检测的方法，属于生物传感器技术领域；通过在铜箔表面制备分子印迹膜，并且印迹不同的肽段分子从而建立分子印迹膜库；在铜箔刻蚀去除后将膜转移到石墨烯表面构建场效应晶体管，借助石墨烯的高灵敏可以实现不同分子的检测；肽段或蛋白可以进入到分子印迹的特异性空腔中，进而引起电信号的变化，实现生物分子的放大检测；该发明首次实现表位分子印迹膜库的建立，证明了方法的通用性，实现了多种生物样品的高特异性，快速、超敏的检测。

咪唑二肽中的至少一种在制造用于逻辑记忆的改善的经口营养组合物中的用途

Resumen de: KR20160146760A

0001 An anti-aging agent derived from a natural product is provided. At least one selected from the group consisting of imidazolidine peptides and metabolites thereof. The present invention also provides an agent for improving neuropsychological function comprising at least one selected from the group consisting of imidazocidepeptides and metabolites thereof as an active ingredient. The present invention is also directed to an agent for modulating the expression of a transporter, such as SLC23A2, containing at least one selected from the group consisting of imidadocidepeptides and metabolites thereof, an imidazocidepeptide and a metabolite thereof An agent for controlling the concentration of cytokine such as IP-10 containing at least one in blood, an expression analysis method for detecting improvement or deformation of neuropsychological function, a kit for detecting improvement or deformation of neuropsychological function .

一种血清α-突触核蛋白种子体外扩增检测方法、试剂盒及其应用

Resumen de: CN122612933A

0001 本发明公开了一种血清α‑突触核蛋白种子体外扩增检测方法、试剂盒及其应用，属于生物医学领域。本发明提供的血清α‑突触核蛋白种子体外扩增检测方法包括以下步骤：将待测血清裂解，离心后收集第一上清液；所述第一上清液经有机溶剂萃取脂质，收集水相；所述水相加入蛋白酶K消化，再次离心后收集第二上清液；所述第二上清液经超滤后收集截留液，得到预处理后的种子富集血清样本；将所述预处理后的种子富集血清样本加入反应液中进行SAA扩增反应。本发明基于新的血清预处理思路和优化的SAA扩增反应条件，提出了一种新的血清α‑突触核蛋白种子体外扩增检测方法及配套试剂盒，以满足标准化、高通量、跨中心一致性的临床检测需求。

用于诊断或辅助诊断绝经后女性认知障碍的试剂盒及应用

Resumen de: CN122612931A

0001 本发明涉及绝经后女性认知障碍诊断技术领域，公开了一种用于诊断或辅助诊断绝经后女性认知障碍的试剂盒及应用。该试剂盒包括用于检测血浆中GFAP、p‑tau181、Orexin‑A等生物标志物表达水平的检测试剂。本发明首次发现并验证了GFAP、p‑tau181等生物标志物在更年期女性认知障碍患者中显著高表达，可作为诊断或辅助诊断的标志物，为绝经后女性认知障碍的早期诊断提供了一种新的、非侵入性的检测手段。

用于诊断阿尔茨海默病的靶标及其检测方法

Resumen de: CN122609706A

本发明属于及医学诊断领域，具体而言，涉及阿尔茨海默病的诊断标志物及其应用。具体地，本发明提供了用于诊断阿尔茨海默病的靶标及其检测方法。更具体地，本发明涉及用于检测样品中UBE2D1基因表达水平的试剂在制备用于诊断阿尔茨海默病或预测阿尔茨海默病风险的组合物或试剂盒中的用途，其中，所述用于检测样品中UBE2D1基因表达水平的试剂包括：用于检测样品中UBE2D1基因的mRNA水平的试剂，用于检测样品中泛素结合酶E2D1水平或泛素结合酶E2D1相关调控蛋白水平的试剂，用于检测UBE2D1基因CpG岛甲基化水平的试剂，或其任意组合。

THERAPEUTIC TARGETING OF TUMOR ESCAPE BY CAR-MEDIATED TROGOCYTOSIS

Resumen de: US20260241002A1

Populations of CAR T cells that exhibit reduced trogocytosis are disclosed, as well as methods for making such cells and methods of using such cells in the treatment of cancer. A reduction in trogocytosis is achieved by inhibiting Cathepsin B in the CAR T cells and/or inducing ubiquitylation of cancer antigens taken up by the CAR T cells.

RNA SIGNATURE TEST FOR DIAGNOSIS OF THORACIC AORTIC ANEURYSM DISEASE

Resumen de: WO2026174031A1

A method for identifying RNA patterns in diagnosis and treatment of thoracic aortic aneurysm disease includes performing RNA sequencing on samples; analyzing the RNA sequencing data with the performance of differential gene expression analysis focusing on differentially regulated pathways to reveal complex regulatory mechanisms; developing a machine learning model to integrate pathway-level interactions; and combining pathway- specific analysis of the RNA patterns with the machine learning model to generate predictions identifying patients likely to be susceptible to thoracic aortic aneurysm disease.

BUTYROPHILIN A2 AND RELATED ISOFORMS FOR THE TREATMENT OF AUTOIMMUNITY AND INFLAMMATION

Resumen de: US20260242441A1

Described herein are methods of reducing CD3-dependent T cell signaling in a subject in need thereof. Also described are method of increasing T-regulatory (Treg) cells, or decreasing T-helper 17 (Th17) cells. These methods involve administering butyrophilin A2 (BTN2A2), a BTN2A2 fragment thereof, a BTN2A2-related isoform, or a BTN2A2-related isoform fragment, or a conjugate or fusion polypeptide comprising any of the foregoing to the subject. These methods are beneficial for patients with autoimmune disorders and inflammatory disorders such as allergy, asthma, glomerulonephritis, inflammatory bowel disease, rheumatoid arthritis, an autoimmune or inflammatory neurological disease, antibody mediated transplant rejection, infantile cholestasis, haemophagocytic lymphohistiocytosis, erythrocytic haemophagocytosis, malnutrition, systemic lupus erythematosus (lupus), psoriasis, myasthenia gravis or HIV. Further described are fusion proteins having BTN2A2 and an Fc domain.

IMMUNE CELL-DERIVED SECRETOME

Resumen de: US20260243757A1

0000 There is provided a composition comprising a secretome obtained by culturing an immune progenitor cell in the presence of an agent that activates the immune cell progenitor to an activated immune cell. Also provided is a composition for use in tissue regeneration, a method of generating a macrophage-derived secretome, a method of screening a drug and a method of culturing a proliferative cell.

PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF AGE-RELATED MUSCULOSKELETAL DISORDERS

Resumen de: US20260240871A1

A composition includes a lysosomal ABCA1 inhibitor. The composition inhibits the transport of cellular ABCA1 to lysosomes or suppresses ABCA1 within lysosomes, by including the lysosomal ABCA1 inhibitor, thereby inhibiting lysosomal cholesterol accumulation and the production of senescence-associated secretory phenotype (SASP) factors. Therefore, the composition can be used for inhibit age-related inflammation, and prevent, improve or treat age-related musculoskeletal disorders.

NOVEL INHIBITORS OF HISTONE METHYLTRANSFERASE NUCLEAR LOCALISATION

Resumen de: US20260242753A1

The present invention relates to novel therapeutic compositions and methods for treating cancer. In particular, the use of proteinaceous inhibitors, including novel bicyclic peptide inhibitors, for use in treating cancer.

MOLECULAR PROBE FUNCTIONALIZED ELEMENT

Resumen de: US20260243761A1

The present invention provides a molecular probe functionalized element comprising a solid base element, a first layer comprising a linker A, a second layer comprising a peptide compound, a third layer comprising a linker B, and a fourth layer comprising a molecular probe, wherein the peptide compound is covalently bound to the solid base element via linker A and the molecular probe is covalently bound to the peptide compound via linker B. The present invention also provides a process for preparing the molecular probe functionalized element and a device comprising the molecular probe functionalized element such as an optical biosensor. Further, the present invention provides a method for detecting a biomarker comprising a) bringing into contact the molecular probe functionalized element with a sample suspected to comprise a target analyte; b) detecting the biomarker based on an interaction between the molecular probe and the target analyte. The present invention also provides a use of the molecular probe functionalized element or of the device for one or more of: a companion diagnostic test; diagnosing Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Diabetes, Huntington, Prion disease, or a tumor in a patient; monitoring of therapy of patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Diabetes, Huntington, Prion disease, or a tumor; and screening of drugs for the treatment of Alzheimer's disease, Parkinson's disease

GQ/11 Protein Peptidomimetics

Resumen de: US20260242759A1

0000 The present invention relates to G protein peptidomimetics, in particular Gprotein peptidomimetics, capable of stabilizing a GPCR, in particular a Gprotein-coupled receptor, in an active conformational state. The G protein peptidomimetics are derived from the α<5 >helix of Gαprotein or mini-Gprotein, in particular they arise from modifications of peptides comprising or consisting of the amino acid sequence set forth in SEQ ID NO:13 or SEQ ID NO:14. The invention further provides complexes of the G protein peptidomimetics and a GPCR, fusion polypeptides of a GPCR and the G protein peptidomimetics and compositions comprising the same. Further disclosed herein are uses of the G protein peptidomimetics, complexes, fusion polypeptides and compositions for determining the structure of a GPCR conformer, for screening for compounds capable of specifically binding to a GPCR conformer and as allosteric modulator of a GPCR and as a biosensor.

METHOD FOR CONTROLLING MEMBRANE POTENTIAL-DEPENDENT ION CHANNEL THROUGH TYPE I TASTE RECEPTORS (T1RS)

Nº publicación: US20260240820A1 20/08/2026

Solicitante:

SAITO MITSUYOSHI [JP]
ION CHAT RES CORPORATE [JP]
SAITO Mitsuyoshi
ION CHAT RESEARCH CORPORATE

Resumen de: US20260240820A1

The present invention pertains to a method for controlling a membrane potential-dependent ion channel (VGSC or the like) through a type I taste receptor present in a nerve cell or the like. In the present invention, it has been found that an Aβ peptide, or a sweet amino acid or an umami substance specifically binds to a type I taste receptor on the surface of a nerve cell to exert an agonist-like or antagonist-like action, thereby amplifying or suppressing a VGSC active current.Moreover, with the binding of an Aβ peptide or the like to a type I taste receptor, the amplification of a VGSC active current occurs, the overactivity of nerve cells causing epileptiform attack occurs, and a large number of substances, which can effectively suppress the amplification of the VGSC active current, among ligand substances that specifically bind to the type I taste receptor, can be found.The present invention provides: a type I taste receptor-specific ligand substance that can control the amplification or suppression of a VGSC active current; and a pharmaceutical composition for preventing or treating various neurodegenerative diseases, such as Alzheimer's disease (AD), due to the amplification of a VGSC active current caused by the binding of an Aβ peptide or the like to a type I taste receptor. Moreover, a method for using, as a target receptor, a type I taste receptor present in a nerve cell or the like to screen a ligand substance for controlling a VGSC or the like in the cell is al